Market Access for Botanical Ingredients: The Dossier
A botanical ingredient can clear customs perfectly and still be unsaleable. The documents that move a shipment — the commercial, transport and analytical pack that importers already know — answer the question of what the goods are and what condition they are in. Market access answers a different question: whether the material, in this form, for this use, in this market, may lawfully be sold at all. The two are routinely confused, because both are piles of paper with overlapping vocabulary, and the confusion is expensive in one direction: a brand that discovers a market-access gap after the ingredient is in the warehouse owns a stock it cannot sell. This guide sets out where the line sits, why the regulatory category decides nearly everything, what an evidence pack has to contain, and who should own the dossier.
The line between customs documents and market access
The import documentation pack exists to get goods across a border. It establishes the identity of the parties, the classification of the goods for duty, the conformity of the shipment with the purchase specification, and the traceability of the lot. It is largely a snapshot of the shipment.
Market access exists at the level of the product category and the use. It asks whether a botanical ingredient may be placed on the market in a given jurisdiction as a food, a supplement, a flavouring, an additive, a cosmetic ingredient or a feed material; under which procedure that placement is allowed; and what must be submitted, notified or authorised before the first sale. It is largely a question of law rather than of goods, and it is settled before production planning starts, not after the shipment arrives.
The practical boundary between the two is easy to state: a customs pack describes a lot; a market-access position describes a use. A supplier can supply a compliant lot of a material whose intended use is not permitted, and no quantity of analysis in the shipment pack will fix that. Equally, a fully authorised use can be delayed for weeks by a shipment pack that is incomplete. The two need different owners, different lead times and different evidence, and the planning error is treating them as one exercise.
The category decides everything
The first market-access question is not what the material is but what it will be sold as. The same botanical extract can sit in several regulatory categories depending on the finished product, the claim attached to it and the market, and the category determines the procedure, the evidence and the timeline.
In broad structure, the categories a botanical ingredient lands in are the food category, where a long history of consumption in a market can matter enormously; the supplement category, where many markets run a notification or a pre-market review route with their own ingredient lists; the flavouring category, where the material is used for taste rather than nutrition and is assessed against its own framework; the additive category, where use is generally tied to a positive list and to defined conditions; the cosmetic category, where the framework is built around safety assessment and a responsible person; and the feed category, where the authorisation logic differs again, as set out in the feed discussion elsewhere on this blog.
The reason the category decides everything is that the evidence requirements do not transfer between categories. A long history of food use supports a food argument and does very little for a cosmetic or feed argument. A safety assessment built for a cosmetic use does not answer a food question. Where a project contemplates selling the same extract into two categories, the honest plan is two positions rather than one, and the earlier the category is settled, the fewer surprises the evidence pack produces.
What the routes usually ask for
The procedures differ by market, but their shapes repeat, and it is the shapes that a planner needs rather than the specific names.
One shape is the authorisation route: a submission is reviewed by a competent body or an authority before the material can be sold for the intended use, and the review asks for a defined set of identity, composition and safety information. This is the shape behind pre-market approval systems for new ingredients and behind feed additive authorisations.
A second shape is the notification route: the material may be sold once a defined information set has been submitted to the authority, and the authority may object within a window. The burden sits on the notifier to have the evidence ready, and the notification is a trigger for scrutiny rather than an approval.
A third shape is the self-determined route: the material may be used if the responsible party has concluded, on documented evidence, that the use meets the applicable standard, and that conclusion and its basis must be defensible on request. No submission is made, but the file has to exist and be maintainable.
A fourth shape is the history-based route: where a market recognises a demonstrated history of consumption of a food, that history can carry the ingredient into the food category without a full new assessment, and the argument turns on the evidence of that history — what was consumed, at what level, in which form, for how long.
Most botanical projects touch more than one shape, because the same extract may be an established food in one market, a notification in a second and an authorisation in a third. The planning consequence is that market access is a per-market exercise and not a global one, and that a single global claim about an ingredient’s regulatory status is almost never accurate.
The evidence pack, and what it has to hold
Whatever the route, the underlying evidence pack has the same five components, and building them is the part of the work that takes time.
Identity comes first, and it is more than a name: the botanical species and plant part, the manufacturing route, and the analytical methods that distinguish the material from its near neighbours. In a trade where substitution is a recognised risk, identity evidence is the foundation everything else rests on.
Composition comes second: what the material contains, on which basis, measured by which methods, including the carrier and any standardisation. History of use comes third, where the route relies on it, and it needs to be documented rather than asserted — what was consumed, in what form, at what level and over what period. Specification comes fourth: the parameter set with its limits, which doubles as the ongoing control after any approval. Safety information comes fifth, in the form the route requires, and it is where the time goes: depending on the route and the use level, the expectation ranges from a structured summary of existing knowledge to new studies commissioned for the purpose.
Two practical notes on the pack. First, the specification should be the same document that governs supply, because a dossier built on a specification the supplier does not actually operate creates a compliance gap that shows up at the first audit. Second, the methods matter as much as the results, because a safety or composition argument built on a method the reviewing authority cannot follow will be questioned.
Who owns the dossier
Ownership of the dossier is a commercial question that is decided too late more often than any technical issue, and it has three realistic answers.
The supplier owns it where the material is sold across markets to many customers and the supplier has invested in the registrations; the buyer then relies on the supplier’s position and needs to verify its scope and currency. The brand owns it where the use, the combination or the claim is specific to the brand, because no supplier dossier can cover what the brand does with the material. And it is shared where the supplier holds the ingredient-level position and the brand holds the finished-product position, which is the most common real-world arrangement and the one that most needs to be written down.
The two failure modes are symmetrical. A buyer who assumes the supplier’s dossier covers the brand’s use discovers at the worst moment that it covers only the ingredient. A supplier who allows a customer to rely on a position whose scope was never checked discovers the same thing from the other side. Both failures are prevented by one paragraph in the supply agreement that names what is covered, what is not, who is the responsible party in each market and who maintains the file.
What to ask a supplier when a route is planned
Four questions sort suppliers quickly on market access. What regulatory positions already exist for this material, in which markets, and can the scope and the evidence be shared. What is the documented history of use of the botanical, and in what form and level, because history-based routes live or die on that document. What analytical methods and identity evidence sit behind the specification, because identity is the foundation of every route. And who has previously used this material for the intended use, if that can be said, because prior use in the same category is the most persuasive evidence of all short of a new study.
A supplier who has thought about market access will answer with documents and scope statements. A supplier who has not will answer with reassurance, and the difference is worth establishing before the development plan is committed rather than after.
The change-control link
A dossier describes the material as it was assessed. Change the material and the dossier’s relationship to reality becomes a question, which is why change control and market access are the same conversation.
The changes that matter most are the ones that do not move the assay: a change of extraction route, a change of carrier, a change of plant or a change of raw material source can alter the composition profile, the process history or the identity basis on which a position rests. This is the same requirement that a change-control clause imposes for quality reasons, and the market-access dimension adds a second consequence to it: a change may not only require a quality re-verification but may reopen a regulatory question in a market where the position was built on a specific process or composition.
Writing the two together is the efficient answer. The supply agreement should require notification of the changes that matter for both purposes, and the market-access file should record which changes would trigger a re-examination, so that the question is answered from the file rather than reconstructed after the fact.
Frequently Asked Questions
Our shipment cleared customs. Does that mean the ingredient can be sold?
No. The customs and shipment pack describes the lot; market access is a question about the use, the category and the market. A shipment can clear with complete documents while the intended use sits outside what the market permits. Settle the category and the route before production planning, not after arrival.
Why does the regulatory category matter so much?
Because the procedures and the evidence do not transfer between categories. History of food use supports a food argument and little else; a cosmetic safety assessment does not answer a food question; feed authorisation has its own logic. Selling the same extract into two categories usually means building two positions.
What belongs in the evidence pack?
Five components: identity evidence covering species, plant part, manufacturing route and the methods that distinguish the material from near neighbours; composition data with bases and methods; documented history of use where the route relies on it; the specification that will also govern supply; and safety information in the form the route requires. Identity is the foundation, and it is the part most often thin.
Who should own the dossier?
Whoever is the responsible party for the position: usually the supplier for an ingredient-level position sold across markets, the brand for a use, combination or claim specific to the brand, and often both in their respective layers. Whatever the arrangement, name it in the supply agreement together with the scope of what is covered, because both failure modes come from an unverified assumption about scope.
Can a formulation change reopen a regulatory position?
It can. Changes that do not move the assay — extraction route, carrier, plant, raw material source — can alter the composition profile or process history on which a position rests. Treat regulatory-relevant changes under the same change-control clause as quality-relevant ones, and record in the market-access file which changes would trigger a re-examination.
